Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 399-404

  Tanaka, Yoshiya ^a   Takeuchi, Tsutomu ^b   Amano, Koichi ^c   Saito, Kazuyoshi ^a   Hanami, Kentaro ^a   Nawata, Masao ^a   Fukuyo, Shunsuke ^a   Kameda, Hideto ^b   Kaneko, Yuko ^b   Kurasawa, Takahiko ^c   Nagasawa, Hayato ^c   Hoshi, Daisuke ^d   Sato, Eri ^d   Yamanaka, Hisashi ^d  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Joint destruction; Rheumatoid arthritis; Switching; TNF inhibitor; Tocilizumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN-6 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; BONE RADIOGRAPHY; BREAST CANCER; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HAQ DISABILITY INDEX; HUMAN; INFECTION; JOINT DESTRUCTION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RETINITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN DISEASE; SKIN ULCER; TOTAL MODIFIED SHARP SCORE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; X RAY ANALYSIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DISEASE COURSE; DRUG EFFECTS; JOINT; MIDDLE AGED; PATHOLOGY; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RETREATMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900428809     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.843757     Document Type: Article

References (25)

1. Bathon JM. Martin RW. Fleischmann RM. Tesser JR. Schiff MH Keystone EC et al. Acomparison of etanercept and methotrexate in patients with early rheumatoid arthritis. NEngl J Med. 2000 ; 343(22): 1586-93
2. Lipsky PE. van Der Heijde DM. St Clair EW. Furst DE Breedveld FC Kalden JR et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infl iximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. NEngl J Med. 2000; 343(22) : 1594-602
3. Weinblatt ME. Keystone EC. Furst DE. Moreland LW. Weisman MH Birbara CA. et al. Adalimumab afully human anti-Tumor necrosis factor alpha monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003; 48(1): 35-45
4. Weinblatt ME. Kremer JM. Bankhurst AD. Bulpitt KJ Fleischmann RM Fox RI et al. Atrial of etanercept arecombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. NEngl J Med. 1999; 340(4): 253-9
5. Nishimoto N. Hashimoto J. Miyasaka N. Yamamoto K Kawai S. Takeuchi T. et al. Study of active controlled monotherapy used for rheumatoid arthritis an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefi t from an x ray readerblinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9): 1162-7
6. Nishimoto N. Miyasaka N. Yamamoto K. Kawai S. Takeuchi T Azuma J Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Signifi cant reduction in Disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19(1): 12-9
7. Smolen J S Beaulieu A. Rubbert-Roth A. Ramos-Remus C. Rovensky J. Alecock E. et al; OPTION Investigators. Eff ect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): Double-blind placebo-controlled randomised trial. Lancet. 2008; 371(9617): 987-97
8. Genovese MC. McKay JD. Nasonov EL. Mysler EF. da Silva NA Alecock E et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58(10): 2968-80
9. Emery P. Keystone E. Tony H P Cantagrel A. van Vollenhoven R Sanchez A et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-Tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67(11): 1516-23
10. Jones G. Sebba A. G u J. Lowenstein M B Calvo A. Gomez-Reino J J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010; 69(1): 88-96
11. Kremer JM. Blanco R. Brzosko M. Burgos-Vargas R. Halland AM Vernon E. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebocontrolled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011; 63(3): 609-21
12. Yamanaka H. Tanaka Y. Inoue E. Hoshi D. Momohara S Hanami K. et al. Effi cacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in Daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011; 21(2): 122-33
13. Takeuchi T. Tanaka Y. Amano K. Hoshi D. Nawata M Nagasawa H et al. Clinical radiographic and functional eff ectiveness of tocilizumab for rheumatoid arthritis patients -REACTION 52-week study. Rheumatology (Oxford). 2011; 50: 1908-15
14. Koike R. Harigai M. Atsumi T. Amano K. Kawai S. Saito K. et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab ahumanized anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Mod Rheumatol. 2009; 19(4): 351-7
15. Prevoo M L van t Hof M A Kuper H H van Leeuwen M A van De Putte LB. van Riel PL. Modifi ed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1): 44-8
16. Aletaha D. Nell VP. Stamm T. Uff mann M. Pfl ugbeil S Machold K Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther. 2005; 7(4): R796-806
17. van Der Heijde D. H ow to read radiographs according to the Sharp/van Der Heijde method. J. Rheumatol 1999; 26(3): 743-5
18. Strand V. Landewe R. van Der Heijde D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. Ann Rheum Dis. 2002; 61(Suppl 2): Ii64-6
19. Kosinski M. Zhao S Z Dedhiya S. Osterhaus J T Ware J E J r. Determining minimally important changes in generic and disease-specifi c health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000 ; 43(7): 1478-87
20. Hubert H B Bloch D A Fries J F. Risk factors for physical disability in an aging cohort: The NHANES I Epidemiologic Followup Study. J Rheumatol. 1993; 20(3): 480-8
21. Bruce B. Fries J F. T he Stanford Health Assessment Questionnaire: Dimensions of practical applications. Health Qual Life Outcomes. 2003; 1: 20
22. Klarenbeek NB. Guler-Yuksel M. van Der Heijde DM. Hulsmans HM Kerstens PJ. Molenaar TH. et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint but not in patients initially treated with infl iximab. Ann Rheum Dis. 2010; 69(12): 2107-13
23. Aletaha D. Alasti F. Smolen JS. Rheumatoid arthritis near remission: Clinical rather than laboratory infl ammation is associated with radiographic progression. Ann Rheum Dis 2011; 70(11): 1975-80
24. Smolen JS. Aletaha D. Grisar JC. Stamm TA. Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010; 69(6) : 1058-64
25. Koike T. Harigai M. Inokuma S. Ishiguro N. Ryu J. Takeuchi T et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Ann Rheum Dis. 2011; 70(12): 2148-51